all report title image
  • Published On : Nov 2021
  • Code : CMI4793
  • Industry : Pharmaceutical
  • Pages : 192
  • Formats :
Ingographics Image

Thalassemia is a term for a group of disorders in which there is reduced levels of hemoglobin, decreased red blood cell production and anemia. There are two main forms – alpha thalassemia and beta thalassemia, each with various subtypes. Beta thalassemia minor, also known as beta thalassemia trait, is a common condition. The symptoms and severity of beta thalassemia varies greatly from one person to another. Individuals with beta thalassemia minor do not develop symptoms of the disorder but may have a mild anemia. Several individuals with beta thalassemia minor go through life never knowing they carry an altered gene for the disorder. A beta thalassemia major diagnosis is usually made during the first two years of life and individuals require regular blood transfusions and lifelong medical care to survive. When the disorder develops later during life, a diagnosis of beta thalassemia intermedia is given; individuals may only require blood transfusions on rare, specific instances. Most beta thalassemia cases are caused by a mutation in the HBB gene. In extremely rare cases, a loss of genetic material (deletion) that includes the HBB gene causes the disorder. Genes provide instructions for creating proteins that play a critical role in many body functions. When a gene mutation occurs, the protein product may be faulty, inefficient, or absent. Depending upon the functions of the particular protein, this can affect several organ systems of the body. Individuals with beta thalassemia minor have a mutation in one HBB gene and are carriers for the disorder. Individuals with beta thalassemia intermedia or major have mutations in both HBB genes.

Market Dynamics

The increasing incidence of beta thalassemia, rising research and development activities for the development of novel therapeutics for the treatment of beta thalassemia, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global beta-thalassemia (B-thal) market over the forecast period.

For instance, in April 2018, GSK, a global pharmaceutical company and Orchard Therapeutics, a pharmaceutical company, entered into a strategic agreement under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK will continue to invest in the development of its platform capabilities in cell and gene therapies, with a focus on oncology.

Moreover, the portfolio of gene therapy programs Orchard had acquired includes, Strimvelis, the first autologous ex vivo gene therapy for children with adenosine deaminase severe combined immunodeficiency (ADA-SCID), approved by the EMA in 2016, two late-stage clinical programs in ongoing registration studies for metachromatic leukodystrophy (MLD) and Wiskott Aldrich syndrome (WAS), and one clinical program for beta thalassemia.

Key features of the study:

  • This report provides in-depth analysis of the global beta-thalassemia (B-thal) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global beta-thalassemia (B-thal) market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Celgene Corp., BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics, CRISPR Therapeutics, DisperSol Technologies, Kiadis Pharma, Incyte Corporation, Editas Medicine, Global Blood Therapeutics, and Syros Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global beta-thalassemia (B-thal) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global beta-thalassemia (B-thal) market

Detailed Segmentation:

  • Global Beta-thalassemia (B-thal) Market, By Treatment:
    • Iron Chelating Drugs
    • Erythroid Maturation Agents
    • Stem Cell Therapy
    • Others
  • Global Polycythemia Vera Therapeutics Market, By Disease Indication:
    • Beta Thalassemia Minor
    • Beta Thalassemia Intermedia
    • Beta Thalassemia Major
  • Global Polycythemia Vera Therapeutics Market, By Region:
    • North America
      • By Treatment
        • Iron Chelating Drugs
        • Erythroid Maturation Agents
        • Stem Cell Therapy
        • Others
      • Disease Indication
        • Beta Thalassemia Minor
        • Beta Thalassemia Intermedia
        • Beta Thalassemia Major
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Treatment
        • Iron Chelating Drugs
        • Erythroid Maturation Agents
        • Stem Cell Therapy
        • Others
      • Disease Indication
        • Beta Thalassemia Minor
        • Beta Thalassemia Intermedia
        • Beta Thalassemia Major
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment
        • Iron Chelating Drugs
        • Erythroid Maturation Agents
        • Stem Cell Therapy
        • Others
      • Disease Indication
        • Beta Thalassemia Minor
        • Beta Thalassemia Intermedia
        • Beta Thalassemia Major
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment
        • Iron Chelating Drugs
        • Erythroid Maturation Agents
        • Stem Cell Therapy
        • Others
      • Disease Indication
        • Beta Thalassemia Minor
        • Beta Thalassemia Intermedia
        • Beta Thalassemia Major
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment
        • Iron Chelating Drugs
        • Erythroid Maturation Agents
        • Stem Cell Therapy
        • Others
      • Disease Indication
        • Beta Thalassemia Minor
        • Beta Thalassemia Intermedia
        • Beta Thalassemia Major
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment
        • Iron Chelating Drugs
        • Erythroid Maturation Agents
        • Stem Cell Therapy
        • Others
      • Disease Indication
        • Beta Thalassemia Minor
        • Beta Thalassemia Intermedia
        • Beta Thalassemia Major
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Celgene Corp. *
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • BlueBird Bio
    • Protagonist Therapeutics
    • Agios Pharmaceuticals
    • Ionis Pharmaceuticals
    • Vifor Pharma
    • Orchard Therapeutics
    • Sangamo Therapeutics
    • CRISPR Therapeutics
    • DisperSol Technologies
    • Kiadis Pharma
    • Incyte Corporation
    • Editas Medicine
    • Global Blood Therapeutics
    • Syros Pharmaceuticals

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment
      • Market Snippet, By Disease Indication
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Pipeline Analysis
    • PEST Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Highlights
    • Reimbursement Scenario
    • Mergers & Acquisitions
  4. Global Beta-thalassemia (B-thal) Market – Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • Impact on Clinical Trials and Drug Development
    • Government Initiatives
  5. Global Beta-thalassemia (B-thal) Market, By Treatment, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Iron Chelating Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Erythroid Maturation Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Stem Cell Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  6. Global Beta-thalassemia (B-thal) Market, By Disease Indication, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Beta Thalassemia Minor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Beta Thalassemia Intermedia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
    • Beta Thalassemia Major
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
  7. Global Beta-thalassemia (B-thal) Market, By Region, 2017 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2017 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Treatment, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Disease Indication, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2017 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Celgene Corp.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BlueBird Bio
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Protagonist Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Agios Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ionis Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Vifor Pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Orchard Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sangamo Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • CRISPR Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • DisperSol Technologies
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Kiadis Pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Incyte Corporation
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Editas Medicine
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Global Blood Therapeutics
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Syros Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 38 market data tables and 31 figures on "Beta-thalassemia (B-thal) Market” - Global forecast to 2028

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo